Succinic Acid

Succinic Acid

SCHEMBL506833

Clc1ccc2c(c1NCc1ccc(Oc3cccnc3)cc1)CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.43
FFAR4 Q5NUL3 2/20 0.42
P2RX3 P56373 3/20 0.39
FFAR1 O14842 2/20 0.39
CYP19A1 P11511 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TBXAS1 P24557 2/20 0.37
NAMPT P43490 1/20 0.36
EGLN2 Q96KS0 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
SCD O00767 1/20 0.34
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL10476217 0.91 FFAR1 (0.47) KDM4CFFAR4FFAR1HTTTDP1
Succinic Acid SCHEMBL10476113 0.86 FFAR1 (0.40) FFAR4FFAR1ALDH1A1HTTTDP1
Succinic Acid SCHEMBL10476214 0.86 FFAR1 (0.38) FFAR4FFAR1HTTEGLN1
Succinic Acid SCHEMBL10476122 0.86 PPARA (0.39) FFAR4P2RX3FFAR1HTT
Succinic Acid SCHEMBL10476142 0.84 HTR2C (0.44) FFAR4P2RX3FFAR1TDP1EGLN1
Succinic Acid SCHEMBL10476129 0.84 WDR5 (0.43) FFAR4FFAR1ALDH1A1TDP1EGLN1
SCHEMBL10228012 0.84 HTR2B (0.43) KDM4CFFAR4FFAR1
Succinic Acid SCHEMBL10476203 0.83 FFAR4 (0.36) FFAR4P2RX3FFAR1TDP1
Succinic Acid SCHEMBL10476192 0.83 SMN1; SMN2 (0.39) FFAR4FFAR1TDP1
Succinic Acid SCHEMBL10476299 0.82 FFAR1 (0.37) FFAR4FFAR1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 KDM4C 881/4885FFAR4 101/4885P2RX3 417/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A KDM4C 611/4885FFAR4 52/4885P2RX3 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.